REPL Replimune Group Inc: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik replimune.com (REPL)

Replimune Group, Inc. (REPL) develops unique oncolytic viruses that destroy tumors, transforming them into sources for their own vaccines. The enterprise value-to-revenue multiple visualizes the real price of the business excluding debt, where 0.00 shows the current value of this metric. The model is based on the RPx platform, which integrates medical centers through exclusive protocols. Replimune Group, Inc. (REPL) maintains its status as a promising innovator with high trust from the scientific community.

Nilai perusahaan marang pendapatan: Replimune Group Inc (REPL) kanggo 23.11.2025 - 20.11.2026

replimune.com - rincian analitis lan metrik utama (REPL)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Replimune Group, Inc. REPL
Sampel barang Replimune Group, Inc.

For Replimune Group, Inc., a developer of cancer immunotherapy, this indicator determines the market value of the business relative to its operating revenues. The metric excludes the impact of debt obligations, revealing the pure fundamental value of the assets. Analyzing the company's valuation based on revenue without accounting for debt allows for the elimination of financial noise. Sharp spikes in the trajectory signal overvaluation amid geopolitical risks that are hindering clinical trials. A stable trend confirms the resilience of the capitalization to external shocks.

Analisis pesaing Replimune Group, Inc.

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IOVA|Multiplikator EV/Sales IMTX (Immatics)|Nilai bisnis marang pendapatan XNCR|compasstherapeutics.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Lyell Pharma|Innate Pharma S.A. (IPHA) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP